Product not yet rated
Includes a Live Web Event on 05/14/2025 at 11:00 AM (PDT)
This session explores the most severe forms of sepsis affecting pregnant and postpartum individuals in the U.S.
Description:
Date: May 14, 2025
Time: 2:00 - 3:00 pm ET / 11:00 am - 12:00 pm PT
Maternal Sepsis Week highlights the urgency of addressing perinatal sepsis, a leading cause of maternal morbidity and mortality. This session explores the most severe forms of sepsis affecting pregnant and postpartum individuals in the U.S., examining their connection to emerging infectious threats. Current treatment guidelines will be applied to critical care scenarios, assessing the effectiveness of different management strategies. The session also focuses on proactive approaches to early detection and intervention, particularly during disease outbreaks, to improve patient outcomes and reduce complications.
Learning Objectives:
At the end of the activity, the learner should be able to:
Describe the severe forms of sepsis affecting pregnant women in the US;
Explain the relationship of severe forms of sepsis to rising endemic and pandemic diseases;
Apply current treatment guidelines to manage cases of critical perinatal sepsis;
Analyze the effectiveness of different treatment strategies for perinatal sepsis.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Jason Vaught, MD
Associate Professor of Gynecology and Obstetrics
Johns Hopkins University School of Medicine
Jason Vaught, MD, is an Associate Professor of Gynecology and Obstetrics, and Surgery at the Johns Hopkins Hospital where he serves as a maternal fetal medicine and critical care specialist. His research studies and clinical expertise include maternal critical illness, cardiac disease in pregnancy, hypertensive disorders of pregnancy, and placenta accreta spectrum.
He has been active in the care of both pregnant and non-pregnant patients within the COVID pandemic. He also serves as the Director of Labor and Delivery at Johns Hopkins Hospital.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.2 contact hours.
Other healthcare professionals will receive a certificate of attendance for 1.0 contact hour.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
Virtual, one-day conference covering a variety of topics in antimicrobial resistance and stewardship
Description
Wednesday, April 30, 2025
According to a 2023 Sepsis Alliance survey, 85% of C-Suite executives in healthcare are concerned that antimicrobial resistance (AMR) may be increasing the potential of another pandemic. Are you ready to fight back?
Designed to explore cutting-edge solutions for antimicrobial resistance (AMR) in healthcare, the 2025 Sepsis Alliance AMR Conference provides a unique opportunity for clinicians, caregivers, patients, and the public to gain practical knowledge from experts and explore innovative approaches for combating AMR. Collaborative effort across sectors, ongoing innovation, and educational initiatives are essential to manage this intricate clinical interplay and tackle the global AMR threat.
As AMR intensifies, the risk of infections progressing to sepsis rises, leading to more challenging cases and adverse outcomes like amputations and fatalities.
We encourage you to attend sessions live, as speakers will be present to answer questions for most sessions. If you cannot attend live, sessions will be available at a later date.
FREE Nursing CE Credits Offered!
Continuing nursing education credits will be available, as will post-event access to resources, ideas, and innovations to improve antimicrobial stewardship. Sepsis Alliance is a Provider approved by the California Board of Registered Nursing, Provider Number CEP17068.
Conference Supporters:
Sepsis Alliance gratefully acknowledges the support provided for this conference by the following sponsors:
Moved to Action: Building a Patient Advocacy Group (CE Session)
Christian John Lillis Chief Executive Officer Peggy Lillis Foundation
11:30-12:00
Track 1: BD Sponsored Session: Best Practices in Blood Culture Quality and Accurate Antimicrobial Susceptibility Testing: Combating AMR and Optimizing Patient Outcomes
Track 1: Jordan Cardinal, PharmD, BCPS Microbiology Medical Science Liaison, U.S. Region, Integrated Diagnostic Solutions, BD
Kayla Kirby, RN, MLS, ASCP Global Medical Science Liaison, BD Diagnostic Solutions
12:00-12:15
Break
12:15-12:45
Bacteriophages: The Next Generation of Antimicrobial Agents (CE Session)
Daria Van Tyne, PhD Associate Professor of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine
12:50-1:20
Amplifying Advocacy: Addressing Antimicrobial Resistance and Fungal Infections (CE Session)
Rob Purdie Managing Director MyCARE
1:25-2:05
Prioritizing Equity in Antimicrobial Stewardship Efforts (EASE): A Framework for Infectious Diseases Clinicians (CE Session)
Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPH, AAHIVP Assistant Professor of Clinical Pharmacy, University of California San Diego
2:05-2:20
Immunexpress Sponsored Session: Sepsis Probability, Antibiotic Stewardship, and Precision Medicine Using SeptiCyte RAPID
Russell R. Miller III, MD, MPH, FCCM Medical Director, Critical Care FirstHealth of the Carolinas
2:25-2:55
Development of an Immunocompromised Antimicrobial Stewardship Program
Hannah Imlay, MD, MS Associate Professor of Medicine Director of Immunocompromised Antimicrobial Stewardship University of Utah Health
2:55-3:35
Artificial Intelligence in Infectious Diseases and Healthcare: Building Bridges to a Real-Time, Learning Health System (CE Session)
Westyn Branch-Elliman, MD, MMSc, FSHEA, FIDSA Acting Director, Health Sciences-AI; Chief, Section of Infectious Diseases; Professor of Medicine at the UCLA David Geffen School of Medicine Veteran Affairs Digital Health Office; Greater LA VA Medical Center
3:35-3:50
Break
3:50-4:15
Track 1: CorMedix Sponsored Session: Reducing Risk of CRBSIs in Hemodialysis Patients: A Multi-Disciplinary Approach
Celina Medina Speaker Advocate
Payal Patel, MD System-Wide Medical Director of Antimicrobial Stewardship, Associate Professor Intermountain Health
4:20-5:05
A Case-Based Approach to Optimizing the Treatment of Antimicrobial-Resistant Gram-Negative Infections (CE Session)
Pranita Tamma, MD, MPH Associate Professor of Pediatrics; Associate Professor, Department of Epidemiology The Johns Hopkins University School of Medicine; The Johns Hopkins Bloomberg School of Public Health
5:10-5:15
Closing Remarks
Hannah Sass
Sepsis Alliance
Please feel free to download, print, display, or share the flyer linked below. It contains a QR code that can be used to register for this conference.
Includes a Live Web Event on 04/23/2025 at 11:00 AM (PDT)
Learn the latest definitions, epidemiology, diagnostic advancements, and treatment protocols for pediatric sepsis.
Description:
Date: April 23, 2025
Time: 2:00 - 3:00 pm ET
Each day, over 200 pediatric cases of severe sepsis are diagnosed in the U.S., and an average of 18 children hospitalized with sepsis die. Additionally, sepsis is missed in up to 8% of children presenting to emergency departments. During this year's Pediatric Sepsis Week (April 20-26, 2025), one of the nation’s leading sepsis experts will provide an in-depth presentation on pediatric sepsis. Dr. Zimmerman will cover the latest sepsis definitions, epidemiology, and pathophysiology for pediatrics. Learners will also explore novel diagnostic advancements, sepsis treatment bundle protocols, and long-term patient outcomes.
Learning Objectives:
At the end of the activity, the learner should be able to:
Describe the contemporary definition of sepsis;
Recall pediatric sepsis epidemiology;
List novel sepsis diagnostic modalities;
Summarize sepsis pathophysiology;
Define sepsis bundled treatment protocols;
State long-term sepsis mortality and morbidity.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Jerry J. Zimmerman, MD, PhD, MCCM
Faculty, Pediatric Critical Care Medicine
Seattle Children's Hospital; Harborview Medical Center University of Washington, School of Medicine
Jerry J. Zimmerman, MD, PhD, MCCM, is a Professor of Pediatrics and Anesthesiology and a senior faculty member in the Division of Pediatric Critical Care Medicine (PCCM) at Seattle Children’s Hospital and Harborview Medical Center, University of Washington School of Medicine. A leader in pediatric critical care research, he has served on numerous national committees dedicated to advancing the field. As co-editor of Pediatric Critical Care, now in its seventh edition, he brings deep expertise in PCCM’s academic landscape.
Dr. Zimmerman has been engaged in sepsis research for over 30 years, earning international recognition for his contributions. He was an inaugural satellite site principal investigator for both the Collaborative Pediatric Critical Care Research Network (CPCCRN) and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Recently, he chaired the Society of Critical Care Medicine’s (SCCM) Discovery Research Network.
His research leadership includes serving as principal investigator for the Life After Pediatric Sepsis Evaluation (LAPSE) study (NCT01415180), which examined long-term outcomes of children with septic shock. He also led the Genotypes and Phenotypes in Pediatric SIRS and Sepsis (GAPPSS) study, evaluating the diagnostic potential of gene mRNA expression signatures (SeptiCyte™) and proteomics in distinguishing bacterial sepsis, severe viral illness, and non-infectious systemic inflammation in critically ill children.
Dr. Zimmerman played a key role in the international PODIUM collaborative, which established modern definitions for single and multiple organ dysfunctions, and led SCCM’s Taskforce in defining the Phoenix Pediatric Sepsis Definition. He is currently a co-principal investigator for the Stress Dose Hydrocortisone in Pediatric Septic Shock (SHIPSS) interventional trial (NCT03401398). A past president of SCCM, Dr. Zimmerman has been honored with distinguished service awards from both SCCM and the American Academy of Pediatrics' Critical Care Section.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.2 contact hours.
Other healthcare professionals will receive a certificate of attendance for 1 contact hour.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
Product not yet rated
Includes a Live Web Event on 04/09/2025 at 11:00 AM (PDT)
Content provided by Prenosis (No CE credits offered)
Webinar Description:
Join Prenosis during this sponsored webinar to explore the impact of AI-driven diagnostics in acute care settings. Learn how FDA-authorized Sepsis ImmunoScore™ enhances traditional early warning systems by using individuals’ biology to identify patients at highest risk for sepsis, or progression to sepsis in 24 hours. Our clinical experts will discuss:
The role of advanced biomarker analysis in improving sepsis detection and diagnosis;
How providers can leverage AI-based technology to complement existing early warning systems and clinical decision support;
The importance of deploying EMR-agnostic tools that integrate in existing clinical workflow;
Use case examples illustrating the use of multi-band tests to indicate risk levels.
This sponsored webinar is ideal for healthcare professionals interested in advancing their approach to sepsis detection and management through AI-based diagnostic technology.
No CE credits are offered for this sponsored webinar. Content was determined by the sponsor.
Webinar Sponsor:
Sepsis Alliance gratefully acknowledges the support provided by Prenosis for this sponsored webinar.
Robin Carver, RN, MSN, CIC
Vice President, Health System Management
Prenosis, Inc.
Robin Carver, RN, MSN, CIC, is a dynamic healthcare executive who bridges clinical care and healthcare technology, bringing over 25 years of experience in the fields of infection prevention, clinical education, and healthcare IT. Currently serving as Vice President of Health System Engagement at Prenosis, she combines her bedside nursing background with her mastery of strategic leadership to drive commercial growth and innovation in precision medicine.
As Director of Infection Prevention at WakeMed, Robin spearheaded initiatives that reduced central line infections by 87% and eliminated ventilator-associated pneumonia in the Medical ICU. Her subsequent work as VP of Member Engagement at Premier helped over 1,300 hospitals demonstrate the tangible impact of data-driven healthcare solutions and improved patient outcomes while optimizing operational efficiency.
Beyond her corporate role, Robin remains deeply committed to her local community, where she draws on her nursing expertise to help individuals and families navigate the complexities of the healthcare system. A passionate advocate for healthcare innovation, Robin combines deep clinical expertise with business acumen to help healthcare organizations navigate the evolving landscape of AI-enabled care delivery. She holds an MSN in Nursing Leadership from East Carolina University.
Jim Sianis, BS, PharmD, MBA
Executive Director, Business Development
Prenosis, Inc.
Jim Sianis, BS, PharmD, MBA, is an accomplished healthcare executive with experience spanning pharmaceutical, healthcare analytics, and diagnostic solutions. As Executive Director of Business Development at Prenosis, he leads the sales and commercialization of Sepsis ImmunoScoreTM, driving the adoption of innovative healthcare solutions grounded in data and real-world evidence.
During his 14-year tenure at Premier, Inc. Jim played a pivotal role in commercializing PINC AI's Healthcare Database, partnering with pharmaceutical, device, and diagnostic companies to create innovative solutions for unmet research needs. He also served at Merck as Medical Science Liaison supporting the anti-infective franchise, conducting high-level discussions with infectious disease thought leaders and supporting successful product launches. Jim worked as a clinical pharmacy specialist in infectious diseases at Lehigh Valley Hospital in Allentown, Pennsylvania, and served as a Hospital Corpsman and Pharmacy Technician in the United States Navy.
Jim combines deep clinical expertise with strong business acumen. His approach to business development is characterized by a strong commitment to integrity, collaboration, and strategic insight, enabling him to bridge the gap between healthcare innovation and commercial success.
In recognition of World Kidney Day on March 13, 2025, this webinar will explore the clinical criteria used to identify AKI in septic patients, highlighting the most relevant diagnostic markers.
Description:
Date: Tuesday, March 11
Time: 2:00 - 3:00 pm ET / 11:00 am - 12:00 PM PT
Sepsis-associated acute kidney injury (AKI) remains a critical complication with significant implications for patient outcomes. In recognition of World Kidney Day on March 13, 2025, this webinar will explore the clinical criteria used to identify AKI in septic patients, highlighting the most relevant diagnostic markers. The complex pathophysiological mechanisms driving kidney dysfunction in the context of sepsis will be examined, emphasizing the interplay between inflammation, hemodynamic instability, and cellular injury. Additionally, this webinar will help healthcare professionals better assess how AKI influences prognosis, considering key risk factors and long-term clinical outcomes.
Learning Objectives:
At the end of the activity, the learner should be able to:
Apply clinical criteria to identify AKI in patients with sepsis;
Analyze the key pathophysiological mechanisms contributing to AKI in patients with sepsis;
Evaluate the prognostic implications of AKI in patients with sepsis based on clinical outcomes and risk factors.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Webinar Supporters:
Sepsis Alliance gratefully acknowledges the support provided for this webinar by the Sepsis Alliance Institute sponsors.
Matthieu Legrand, MD, PhD
Professor and Director of Clinical Research, Department of Anesthesia and Perioperative Medicine
University of California, San Francisco
Matthieu Legrand, MD, PhD, is a clinician scientist practicing critical care medicine and anesthesiology. His research interests focus on the development and validation of acute illness biomarkers, mostly in the setting of sepsis, septic shock, and Acute Kidney Injury, intending to improve the non-optimal performance of current diagnostic methods. He has investigated diagnostic and therapeutic interventions associated with outcomes in severely ill patients with sepsis, being the principal investigator of several clinical trials. He was Full Professor of Anesthesiology and Critical Care Medicine and Medical Director of the surgical ICU and Burn ICU at Paris Diderot University before moving to the University of California - San Francisco (UCSF) in 2019. Dr. Legrand is now Professor and Director of Clinical Research in the department of Anesthesiology and Perioperative Medicine at UCSF.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.2 contact hours.
Other healthcare professionals will receive a certificate of attendance for 1.0 contact hour.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
Please feel free to download, print, display, or share the flyer linked below. It contains a QR code that can be used to register for this webinar/course.
Content provided by Vantive (No CE credits offered)
Webinar Description:
Endotoxin plays a prominent role in the pathogenesis of sepsis and often comes from the gut and the idea of neutralizing its detrimental capacities. All Gram-negative bacteria have a cell wall made up of endotoxins and can activate the immune system in many ways at low or toxic level. Eight out of 12 of the most dangerous bacteria cited by the World Health Organization to encourage treatment strategies are gram negative species. In addition to delving into early recognition and treatment of sepsis using the bundles, this sponsored session will explore recognition of endotoxin and innovative treatment options.
No CE credits are offered for this sponsored webinar. Content was determined by the sponsor.
Webinar Sponsor:
Sepsis Alliance gratefully acknowledges the support provided by Vantive for this sponsored webinar.
Kathleen M. Vollman, MSN, RN, CCNS, FCCM, FCNS, FAAN
Clinical Nurse Specialist/Consultant
ADVANCING NURSING, LLC
Kathleen M. Vollman MSN, RN, CCNS, FCCM, FCNS, FAAN, is a Critical Care Clinical Nurse Specialist and Consultant. Kathleen received her BSN from Wayne State University in Detroit and her Master as Critical Care Clinical Nurse Specialist from California State University Long Beach. She has published and lectured nationally and internationally on a variety of topics including pulmonary, critical care, prevention of health care acquired injuries including pressure injury and CAUTI/CLABSIs and other HAIs, work culture, and sepsis recognition and management. She serves as a subject matter expert on these topics for the American Hospital Association and Michigan Hospital Association. From 1989 to 2003, she functioned in the role of Clinical Nurse Specialist for the Medical ICUs at Henry Ford Hospital in Detroit, Michigan. Currently, her company, ADVANCING NURSING LLC, is focused on creating empowered work environments for healthcare practitioners through the acquisition of better skills, attainment of greater knowledge, and implementation of process improvement.
Please feel free to download, print, display, or share the flyer linked below. It contains a QR code that can be used to register for this webinar/course.
Hear directly from sepsis survivors about their personal experiences, and learn about the sepsis education, resources, and support services that have made a meaningful impact for survivors and their loved ones.
Description:
Original Broadcast Date: February 13, 2025
Join us during Sepsis Survivor Week 2025 to hear from sepsis survivors about their personal sepsis experiences. We’ll also share the sepsis education, resources, and support services to assist during transitions of care within the hospital, at discharge, and beyond. Attendees will learn what information and resources made a meaningful impact for these sepsis survivors and caregivers to feel supported during the acute, critical, and post-sepsis phases of their sepsis experiences, and what they wish they would have known then.
This presentation will also provide an in-depth overview of the free patient education, tools, survivor and caregiver resources, and support services Sepsis Alliance has available, with special attention on Sepsis Alliance Connect. Whether you’re a frontline healthcare professional, administrator, or sepsis advocate, this presentation will equip you with the knowledge and tools needed to make a difference and level up your sepsis patient education and transitions of care practices and programs.
Learning Objectives:
At the end of the activity, the learner should be able to:
List key transition of care opportunities for patient education and support both during their acute care stay and critical illness, as well as post-sepsis;
Identify strategies to support sepsis survivors and their caregivers throughout the continuum of care;
Describe how to use available resources to plan a successful discharge process, improve long-term outcomes and reduce the need for readmission.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Webinar Supporters:
Sepsis Alliance gratefully acknowledges the support provided for this webinar by the Sepsis Alliance Institute sponsors.
Hailey Bain
Sepsis Survivor & Patient Partner
Sepsis Canada
Hailey is a survivor of septic shock from Toronto, Canada. Her sepsis experience was derived from appendicitis being misdiagnosed at 23 years old, which has led her to be passionate about patient advocacy and sharing her experience to improve outcomes for sepsis patients. Currently, she is a Patient Partner at Sepsis Canada and an active member of their Patient Advisory Council. Hailey also has a professional background in Human Resources across various industries, and is currently pursuing a certificate program on Critical Care and Sepsis Health Research.
Myrna Pair
Sepsis Survivor
Myrna Pair is a severe sepsis and septic shock survivor. In May 2020, emergent exploratory abdominal surgery led to removing her infected dying colon followed by construction of an ileostomy. Since then, the ostomy was reversed in 2021, open mesh surgery to repair three incisional hernias and one inguinal hernia occurred in 2024, and bowel issues continue since the ostomy reversal.
Rand Conroe
Sepsis Survivor
Rand is a sepsis survivor who previously spent 12 years in the US Army as a Russian/Korean linguist, followed by 10 years working in the defense industry as a Group Manager for General Dynamics. He has run a small chain of health clubs, owned a Country Western nightclub, and is now in the Health Care industry as the Executive Director of a Independent/Assisted Living facility in Southern Colorado.
Megan Jones
Director, Community Education and Support
Sepsis Alliance
Megan Jones joined Sepsis Alliance in 2021 after relocating from Charlotte, NC, where she was the Community Engagement and Program Coordinator for Community Building Initiative. With a background in communications, program management, and events, as well as a passion for diversity, equity, and inclusion, she has embraced the role of Senior Community and Content Manager, overseeing all of Sepsis Alliance’s Patient and Public-facing programming, including Sepsis Alliance Connect. Outside of work, Megan loves choral singing and exploring the outdoors. She enjoys exploring hiking trails in the San Diego area with her rescue dog, Shadow.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.2 contact hours.
Other healthcare professionals will receive a certificate of attendance for 1.0 contact hour.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
Please feel free to download, print, display, or share the flyer linked below. It contains a QR code that can be used to register for this webinar/course.
Content provided by Inflammatix (No CE credits offered)
Webinar Description:
This sponsored session will present the unmet needs in assessing patients for suspected acute infection and sepsis, the promise of host response as a better approach to address these needs, and how the TriVerity™ Test System (Inflammatix, Inc.) may be used in routine care once cleared.
No CE credits are offered for this sponsored webinar. Content was determined by the sponsor.
Webinar Sponsor:
Sepsis Alliance gratefully acknowledges the support provided for this webinar by Inflammatix.
Sam Ajizian, MD
Chief Medical Officer
Inflammatix
Sam Ajizian, MD, came to Inflammatix as Chief Medical Officer after nearly 10 years at Medtronic, serving in CMO roles in the Acute Care & Monitoring businesses. He oversaw a global business serving over 115 million patients a year in over 70 countries. He is a proven global leader in the medical device community, engaging key medical societies worldwide and driving adoption of products through research, guidelines, and education. He is energized by customers and how to best meet their needs.
Please feel free to download, print, display, or share the flyer linked below. It contains a QR code that can be used to register for this webinar/course.
One-hour live webinar discussing how the CDC is working with partner organizations across the nation to advance and support continuous sepsis quality improvement work and outcomes.
Keywords: Quality Improvement; QI; Sepsis
Description:
Date: January 16, 2025
Time: 3:00 - 4:00 pm ET / 12:00 pm - 1:00 pm PT
During this webinar, the Director of the Center for Disease Control and Prevention’s (CDC) National Center for Emerging and Zoonotic Infectious Diseases in the Division of Healthcare Quality Promotion will review how CDC is working with partner organizations across the nation to advance and support continuous sepsis quality improvement work and outcomes.
Attendees will gain valuable insights into upcoming CMS and CDC-developed measures that will deliver actionable data, enhancing hospitals' ability to provide effective care for patients with sepsis.
Learning Objectives:
At the end of the activity, the learner should be able to:
Identify how CDC is working with partners to advance sepsis quality improvement and how these strategies could be applied to advance sepsis quality improvement at their own organization.
Describe how forthcoming CMS and CDC-developed measures will provide insight and actionable data on how hospitals are able to care for patients with sepsis.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Michael Bell, MD
Director, Center for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion
Department of Health and Human Services, Centers for Disease Control and Prevention (CDC)
Michael Bell, MD, is the Director of National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) Division of Healthcare Quality Promotion (DHQP). He served as Deputy Director of DHQP from 2010 to 2023 before being selected as Acting Director and ultimately Director in 2024.
DHQP promotes the protection of patients and healthcare personnel and improvements in the safety and quality of health care. Examples of activities include producing guidelines for the prevention of healthcare-associated infections (HAI), programs for combating antimicrobial resistance (AR), and improvements in basic safe medical practices such as safe injections.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.2 contact hours.
Other healthcare professionals will receive a certificate of attendance for 1.0 contact hour.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
Financial Relationship Disclosure for All Individuals in Control of Content
All individuals in control of content for this event, including planning committee members, presenters, and reviewers, had no relevant financial relationships to disclose.
Please feel free to download, print, display, or share the flyer linked below. It contains a QR code that can be used to register for this webinar/course.
Healthcare-associated infections (HAIs) are the most common challenge in hospital settings, posing significant risks for both patients and healthcare providers. According to the Centers for Disease Control and Prevention (CDC), one in every 31 hospital patients contracts at least one HAI daily, leading to substantial financial burdens for healthcare organizations. The risk of HAIs escalating into sepsis underscores the critical need for effective prevention measures.
Healthcare professionals must prioritize the identification and implementation of strategies to improve performance and outcomes in preventing HAIs and sepsis across all departments and specialties.
Sepsis Alliance is hosting the 2024 Sepsis Alliance Symposium: Healthcare-Associated Infections to continue our mission and further the idea that infection prevention is sepsis prevention. This engaging virtual event will take place on December 12, 2024, and will delve into essential topics surrounding HAIs. Attendees will gain access to cutting-edge clinical insights and the latest recommendations for preventing and treating infections. This half-day symposium aims to highlight the importance of HAI prevention in clinical practice, ultimately striving to improve patient outcomes and reduce the incidence of sepsis.
Central line-associated bloodstream infections (CLABSI)
HAI surveillance: Past, present, and future
Preventing healthcare-associated infections in surgical patients
Learning Objectives:
At the end of the activity, the learner should be able to:
Demonstrate increased knowledge relating to maintaining a compliant and effective infection prevention and control program in the healthcare setting;
Describe examples of infection prevention and control evidence-based best practices and recommendations;
Propose innovative approaches, protocols, tools and documentation for limiting healthcare-associated infections.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Symposium Supporters:
Sepsis Alliance gratefully acknowledges the support provided for this symposium by the following sponsors:
Kidney Care
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 4.2 contact hours.
Other healthcare professionals will receive a certificate of attendance for 3.5 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
Welcome & Opening Remarks
Time: 10:00 - 10:10 AM ET
Session 1 Infection Prevention in Action: Partnering to Enhance Healthcare-Associated Infections (HAIs) and Sepsis Prevention Strategies
Time: 10:10 - 10:40 AM ET
This presentation will discuss the similarities in prevention approaches for HAI and sepsis. Learn how interdisciplinary collaboration among healthcare professionals and infection preventionists can significantly enhance infection prevention efforts to minimize both HAIs and preventable sepsis risks. This presentation aims to equip attendees with the necessary knowledge to improve patient outcomes through effective infection prevention practices.
Learning Objectives:
Identify and compare the prevention strategies for healthcare-associated infections (HAIs) and sepsis, highlighting both their shared approaches and unique considerations;
Describe how interdisciplinary collaboration among healthcare professionals, infection preventionists, and other stakeholders enhances the effectiveness of prevention efforts;
Recognize common barriers to implementing HAI and sepsis prevention strategies and discuss actionable solutions to address these challenges in healthcare settings.
Session 2 HAP, VAP, and All of That
Time: 10:40 - 11:10 AM ET
During this presentation, learners will have the opportunity to review the definitions and epidemiology of ventilator-associated events, ventilator-associated pneumonia, and non-ventilator hospital-acquired pneumonias. The session will also explore the pathophysiology and impact of co-infections related to hospital-acquired pneumonias, as well as strategies to prevent hospital-acquired pneumonia.
Learning Objectives:
Understand the definitions and epidemiology of ventilator-associated-events, ventilator-associated pneumonia, and non-ventilator hospital-acquired pneumonia;
Describe the epidemiology and pathophysiology of hospital-acquired pneumonias, including the impact of co-infections;
Recognize strategies to prevent pneumonia within the hospital.
Sponsor Session 1 BD Sponsored Session: Clinical Burden of Hospital Onset Bacteremia and Fungemia (HOB)
Time: 11:25 - 11:40 AM ET
Hospital Onset Bacteremia & Fungemia (HOB) is a new metric proposed by the CDC for National Healthcare Safety Network (NHSN) volunteer reporting. This sponsored presentation will delve into recent research papers that elucidate the differences between HOB and Central Line-associated Bloodstream Infection (CLABSI), the impact of urine sources on Catheter Associated Urinary Tract Infections (CAUTI) and non-catheter Hospital Onset UTIs contributing to HOB, the burden of Surgical Site Infections (SSI) associated with HOB, and the overall clinical and health economic significance of HOB.
Session 3 Health Inequity in Healthcare-Associated Infections and Antimicrobial Resistance
Time: 11:40 AM - 12:10 PM ET
This presentation explores the complex relationship between healthcare-associated infections (HAIs), antimicrobial resistance (AMR), and health inequities. Recent evidence that highlights disparities in HAI and AMR burdens will be examined, identifying critical factors that drive these inequities including variations in care quality and social determinants of health. Insights into targeted interventions designed to address and reduce these disparities, contributing to more equitable outcomes in infection prevention and resistance management, will also be discussed.
Learning Objectives:
Review current evidence of inequities in the burden of healthcare-associated infections (HAIs) and antimicrobial resistance (AMR);
Describe how differences in quality of care and social determinants of health can contribute to HAI and AMR risk;
List interventions that may help us to eliminate inequities in HAI and AMR risk
Sponsor Session 2 BD Sponsored Session: The Impact of Drug-Resistant Infections in the Cancer Community
Time: 12:10 - 12:40 PM ET
Nearly 100 years ago, scientists handed the world a new miracle drug: antibiotics. This revolutionized healthcare, improving the length and quality of our lifespans. Modern medicine has been built on the bedrock of being capable of controlling infections while treating aggressive disease. We stand on the precipice of losing this ability, as antimicrobial resistance (AMR) threatens to overwhelm our antibiotic and antifungal supply. Nowhere is this more concerning than in the cancer community. This sponsored presentation will review current literature analyzing the impact of AMR on the cancer community and will provide an overview of suggested actions we can take to reduce the risk of drug-resistant infections.
Session 4 Prevention of CRBSIs in Healthcare Settings
Time: 12:55 - 1:25 PM ET
This presentation focuses on preventing catheter-related bloodstream infections (CRBSIs) in healthcare settings, highlighting the critical role of identifying and mitigating sources of infection. Attendees will gain insights into effective strategies for reducing the risk of these infections, with a special focus on antimicrobial lock therapy as a preventative measure. The session aims to equip healthcare professionals with practical knowledge to enhance patient safety and infection control practices related to intravascular catheter use.
Learning Objectives:
Identify the predominant sources of microbes causing intravascular catheter infections;
List strategies to reduce risk of intravascular catheter infections;
Describe antimicrobial lock therapy for prevention of intravascular catheter infections.
Session 5 Compendium of Strategies to Prevent CAUTIs: 2022 Updates
Time: 1:25 - 1:55 PM ET
This presentation offers a comprehensive overview of the latest methods to prevent catheter-associated urinary tract infections (CAUTIs). Recent changes and additions to the CAUTI Compendium, providing participants with updated strategies to minimize infection risks, will be covered. Attendees will also learn how to incorporate diagnostic and antimicrobial stewardship into their CAUTI prevention practices effectively. Additionally, the differences between infectious and noninfectious harms linked to CAUTIs will be explored, equipping healthcare professionals with the knowledge to improve patient outcomes.
Sponsor Session 3 CorMedix Sponsored Session: Reducing the Risk of Catheter Related Blood Stream Infections in Hemodialysis Patients
Time: 1:55 - 2:10 PM ET
In this sponsored session, learn about the risks of catheter related blood stream infections in hemodialysis patients. Opportunities for prevention will also be discussed, including the clinical data for a recent FDA-approved catheter lock solution. The presenter will cover ways for healthcare teams to work together to improve patient outcomes.
Sponsor Session 4 Wolters Kluwer Sponsored Session: SIR, SUR & CAD: Evaluate & Elevate Your Infection Prevention & Control Performance
Time: 2:10 - 2:25 PM ET
Infection Prevention leaders are often challenged with how to best evaluate their Infection Prevention & Control (IPC) program performance while also considering the unique attributes of their organization and patients they serve. As 2024 comes to a close, now is the time to revisit key performance indicators such as Standardized Infection Ratio (SIR), Standardized Utilization Ratio (SUR), and Cumulative Attributable Difference (CAD) to further enhance your IPC program in the new year. This Wolters Kluwer sponsored session recaps best practices when evaluating your IPC program performance, including reviewing the role of risk adjustment, discussing the value of readily available metrics, and sharing tips to consider in your own practice. Join our expert to ensure your program is set up for success in 2025!
Session 6
Strategies for Preventing C. difficile Infections in Hospitals
Time: 2:25 - 2:55 PM ET
This presentation will explore the current landscape of C. difficile infections in U.S. hospitals, emphasizing the urgency of addressing this persistent healthcare challenge. Attendees will gain insights into the most effective infection prevention strategies, including well-established and emerging practices. The session will also address the complexities and ongoing debates around additional preventative measures, offering a comprehensive understanding of how hospitals can enhance patient safety and reduce infection rates.
Learning Objectives:
Define trends in C. difficile infections in the US;
Identify essential strategies that all hospitals should implement for prevention of C. difficile infections;
Describe additional and unresolved strategies for prevention of C. difficile infections in hospitals.
Session 7 Update on Strategies to Prevent Surgical Site Infections
Time: 2:55 - 3:25 PM ET
During this presentation, learners will gain an understanding of the burden of Surgical Site Infections (SSIs) and the importance of infection prevention and control in the surgical population. Attendees will also gain insights into ways to improve SSI infection prevention competency and protocols.
Learning Objectives
Restate the burden of SSIs and importance of prevention;
Define ways to improve competency in preventing surgical site infections in acute care hospitals.
Closing Remarks: Key Takeaways
Time: 3:25 - 3:30 PM ET
Time (ET)
Session Title
Presenter
10:00-10:10
Welcome and Opening Remarks
10:10-10:40
Session 1: Infection Prevention in Action: Partnering to Enhance Healthcare-Associated Infections (HAIs) and Sepsis Prevention Strategies
Stephanie Holley, MBA, BSN, RN, CIC, FAPIC Director IPC Education and Professional Development Association of Professionals in Infection Control and Epidemiology (APIC)
10:40-11:10
Session 2: HAP, VAP, and All of That
Kelly Cawcutt, MD, MS, FACP, FIDSA, FCCM Associate Professor, Infectious Diseases & Critical Care Medicine Medical Director of Infection Control
University of Nebraska Medical Center
11:10-11:25
Break
11:25-11:40
BD Sponsored Session: The Impact of Drug-Resistant Infections in the Cancer Community
Diane Flayhart, MS Director, Global Public Health BD
11:40-12:10
Session 3: Health Inequity in Healthcare-Associated Infections and Antimicrobial Resistance
David Calfee, MD, MS Director of the Healthcare-Associated Infections Division / Senior Science Advisor Center for Quality Improvement and Patient Safety (CQuIPS) Agency for Healthcare Research and Quality, US Department of Health and Human Services
12:10-12:40
BD Sponsored Session: Clinical Burden of Hospital Onset Bacteremia and Fungemia (HOB)
Kalvin Yu, MD, FIDSA
Vice President of Medical Affairs, North America, BD Samantha Bastow, PharmD, MBA Associate Director, Clinical Integration, Medical Affairs, US Region, BD
12:40-12:55
Break
12:55-1:25
Session 4: Prevention of CRBSIs in Healthcare Settings
Leonard A. Mermel, DO, ScM, AM (Hon), FSHEA, FIDSA, FACP Professor of Medicine Warren Alpert Medical School of Brown University
Medical Director, Dept. of Epidemiology & Infection Prevention Brown University Health
Adjunct Clinical Professor University of Rhode Island College of Pharmacy
1:25-1:55
Session 5: Compendium of Strategies to Prevent CAUTIs: 2022 Updates
Payal Patel, MD, MPH, FIDSA System-Wide Medical Director of Antimicrobial Stewardship, Associate Professor Intermountain Health
1:55-2:10
CorMedix Sponsored Session: Reducing the Risk of Catheter Related Blood Stream Infections in Hemodialysis Patients
Anil Agarwal, MBBS, MD, FACP, FASN, FISN, FNKF, FASDIN Professor of Medicine University of California San Francisco
2:10-2:25
Wolters Kluwer Sponsored Session: SIR, SUR & CAD: Evaluate & Elevate Your Infection Prevention & Control Performance
Matt Weissenbach, DrPH, CPH, CIC, FAPIC Senior Director of Clinical Affairs Wolters Kluwer
2:25-2:55
Session 6: Strategies for Preventing C. difficile Infections in Hospitals
Larry K. Kociolek, MD, MSCI, FSHEA, FPIDS Vice President, System Preparedness, Prevention, and Response; Attending Physician, Division of Infectious Diseases; Ann & Robert H. Lurie Children’s Hospital of Chicago
2:55-3:25
Session 7: Update on Strategies to Prevent Surgical Site Infections
Deverick (“Dev”) J. Anderson, MD, MPH, FIDSA, FSHEA Director, Duke Center for Antimicrobial Stewardship and Infection Prevention
Professor of Medicine Division of Infectious Diseases, Duke University Medical Center
Anil K. Agarwal, MD, FACP, FASN, FISN, FNKF, FASDIN, is the Chief of Medicine at Veterans Affairs Central California Health Care System at Fresno, California and a Professor of Clinical Medicine at The University of California San Francisco at Fresno. Dr. Agarwal is a passionate clinician, educator, and author, and is an internationally recognized expert in hypertension, chronic kidney disease, dialysis, anemia, mineral bone disorders, and vascular access. He has conducted over 50 clinical trials, developed protocols, and published results of studies. He is a frequently sought speaker nationally and internationally. He serves and chairs many committees and boards, and also serves as editor and reviewer for several medical journals.
Deverick (“Dev”) J. Anderson, MD, MPH, FIDSA, FSHEA
Director, Duke Center for Antimicrobial Stewardship and Infection Prevention; Professor of Medicine
Division of Infectious Diseases, Duke University Medical Center
Deverick (Dev) Anderson, MD, MPH, FIDSA, FSHEA, is a Professor of Medicine in the Duke University School of Medicine. He is Director of the Duke Center for Antimicrobial Stewardship and Infection Prevention. Over two decades, Dr. Anderson’s work has led to improvements in the quality and safety of care in multiple areas of healthcare, including Duke University Hospital and more than 60 community hospitals in the southeastern U.S. through the Center’s outreach networks, the Duke Infection Control Outreach Network (DICON) and the Duke Antimicrobial Stewardship Outreach Network (DASON).
Dr. Anderson is recognized as an international expert in healthcare epidemiology and multidrug-resistant pathogens. He is currently a Fellow of the Infectious Disease Society of America (IDSA) and a Fellow of the Society for Healthcare Epidemiology of America (SHEA). Dr. Anderson has authored over 300 published articles related to healthcare epidemiology, quality of care, patient safety, antimicrobial stewardship, and multidrug-resistant pathogens. Dr. Anderson has received research funding from the NIH, AHRQ, and CDC and is currently the Principal Investigator of the Duke-UNC Prevention Epicenter Program.
Samantha Bastow, PharmD, MBA
Associate Director, Clinical Integration, Medical Affairs, US Region
BD
As the Associate Director of Clinical Integration in Medical Affairs at BD, Samantha Bastow, PharmD, MBA, is responsible for overseeing and managing both the clinical and administrative aspects of the medical division of business. This includes innovation and new product and business development, lifecycle clinical evidence generation, market shaping and development, and safety and compliance. Prior to BD, she served as the Director of Clinical Pharmacy Services at the University of Chicago Medical Center, where she led inpatient and emergency clinical pharmacy service lines, including antimicrobial stewardship, in addition to formulary management, clinical decision support, business development, research and academic responsibilities. Samantha holds a PharmD from Palm Beach Atlantic University and an MBA with a specialization in data analytics from the University of Illinois. She completed a PGY1 residency at Sarasota Memorial Hospital followed by an emergency medicine pharmacy residency at Boston Medical Center.
David Calfee, MD, MS
Director of the Healthcare-Associated Infections Division / Senior Science Advisor
Center for Quality Improvement and Patient Safety (CQuIPS), Agency for Healthcare Research and Quality, US Department of Health and Human Services
David P. Calfee, MD, MS, is an infectious disease physician and healthcare epidemiologist who serves as Senior Science Advisor and the Director of the Healthcare-Associated Infection (HAI) Division within the Center for Quality Improvement and Patient Safety (CQuIPS) at the Agency for Healthcare Research and Quality (AHRQ). Prior to joining AHRQ, Dr. Calfee was a Professor of Medicine and Population Health Sciences at Weill Cornell Medicine, in New York, NY. He also served as the Chief Hospital Epidemiologist for NewYork-Presbyterian/Weill Cornell Medical Center. He has more than 20 years of experience in implementation and management of infection prevention and control programs and has conducted clinical research on healthcare-associated infections, antimicrobial resistance, and antimicrobial stewardship in a variety of healthcare settings. He currently also serves as the Editor-in-Chief of Infection Control & Hospital Epidemiology.
Kelly Cawcutt, MD, MS, FACP, FIDSA, FCCM
Associate Professor, Infectious Diseases & Critical Care Medicine / Medical Director of Infection Control
University of Nebraska Medical Center
Kelly Cawcutt, MD, MS, FACP, FIDSA, FCCM, is an Associate Professor of Medicine and board certified in Critical Care Medicine and Infectious Diseases at University of Nebraska Medical Center (UNMC) in Omaha. She is the Medical Director of Medical Quality and an Associate Director of Infection Prevention and Hospital Epidemiology for Nebraska Medicine; and Co-Director of Digital Innovation and Social Media Strategy for the Infectious Diseases Division of UNMC. Nationally, she is involved with the Infectious Diseases Society of America (IDSA), the Society of Critical Care Medicine (SCCM), and the Society for Healthcare Epidemiology of America (SHEA). Dr. Cawcutt’s research interests include infections in the intensive care unit, with focus on hospital-acquired infections.
Diane Flayhart, MS
Director, Global Public Health
BD
As a Director in Global Public Health at BD, Diane Flayhart, MS, is responsible for leading global policy and advocacy efforts on antimicrobial resistance. She works with global stakeholders in a collaborative and programmatic approach to strengthen healthcare systems. She also leads efforts for the Antimicrobial Resistance Fighter Coalition, a global organization that seeks to increase awareness of drug-resistant infections and encourage action. Prior to joining BD, Diane managed the clinical microbiology laboratory at The Johns Hopkins Hospital.
Stephanie Holley, MBA, BSN, RN, CIC, FAPIC
Director IPC Education and Professional Development
Association of Professionals in Infection Control and Epidemiology (APIC)
Stephanie Holley, MBA, BSN, RN, CIC, FAPIC, has been an infection preventionist for the past 25 years. She began her healthcare journey as a registered nurse providing care for med/surg and oncology patients and spent time in the perioperative environment. She made a move from direct patient care to joining the University of Iowa’s Program of Hospital Epidemiology where she was the Lead Infection Preventionist. Recently, Stephanie transitioned from a member to staff role at the Association for Professionals in Infection Control and Epidemiology (APIC), where she now serves as Director of Infection Prevention & Control (IPC), Education & Professional Development.
Larry K. Kociolek, MD, MSCI, FSHEA, FPIDS
Vice President, System Preparedness, Prevention, and Response
Ann & Robert H. Lurie Children’s Hospital of Chicago
Larry K. Kociolek, MD, MSCI, FSHEA, FPIDS, is an Attending Physician in the Division of Pediatric Infectious Diseases and Vice President of System Preparedness, Prevention, and Response at Ann & Robert H. Lurie Children’s Hospital of Chicago, and he is an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. At Lurie Children’s, Dr. Kociolek leads preparedness, prevention, and response efforts for all hazards, including emerging pathogens. He serves as site PI for the HRSA-funded Pediatric Pandemic Network.
Dr. Kociolek is the Principal Investigator of several NIH-funded translational research studies focused on the epidemiology and prevention of healthcare-associated and other high-consequence infections in children, particularly C. difficile infection and COVID-19. He serves on the Pediatric Leadership Council for the Society for Healthcare Epidemiology of America (SHEA) whose goal is to lead national advocacy, research, and education efforts for prevention of healthcare-associated infections in children. Through SHEA, he has led an international group of experts to define best practices for the prevention of C. difficile infections in adults and children in acute care hospitals.
Leonard A. Mermel, DO, ScM, AM (Hon), FSHEA, FIDSA, FACP
Professor of Medicine
Warren Alpert Medical School of Brown University
Leonard A. Mermel, DO, ScM, AM (Hon), FACP, FIDSA, FSHEA, is a Professor of Medicine at Warren Alpert Medical School of Brown University, an Adjunct Clinical Professor at the University of Rhode and College of Pharmacy, and a Medical Director of the Department of Epidemiology & Infection Prevention for the Lifespan Hospital System. Dr. Mermel was a Technical Expert Panel Member of the Center for Medicare & Medicaid Services (CMS) Patient Safety Monitoring System and is a Subject Matter Expert for the AHRQ Safety Program for HAI Prevention. He was 2005 President of the Society for Healthcare Epidemiology of America (SHEA) and the 2014 SHEA Mentor Scholar Award recipient.
Dr. Mermel is a member of the World Health Organization (WHO) Guideline Development Group for the prevention of bloodstream infections and other infections associated with intravascular catheters. He has co-authored U.S. guidelines dealing with prevention and management of intravascular catheter infections and co-authored 400 articles, textbook chapters, and abstracts dealing with infection prevention and infectious diseases. As of October 2024, his H-Index is 58 and Sum of Times Cited is 32,119. Drs. Mermel and Classen developed the idea for the Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals, a standard guidance used in the U.S. and the basis for some National Patient Safety Goals. He is Co-Course Director of the Annual Fellows Course in Healthcare Epidemiology, Infection Prevention, and Antimicrobial Stewardship. He has lectured at the National Institutes of Health, Institute of Medicine, NASA Johnson Space Center, and internationally on infectious disease issues. His research focus has been the prevention of healthcare-associated infections.
Payal Patel, MD
System-Wide Medical Director of Antimicrobial Stewardship, Associate Professor
Intermountain Health
Payal Patel, MD, is an associate professor at Intermountain Health and the systemwide medical director of antimicrobial stewardship. She is an infectious diseases physician and is passionate about improving patient safety and antimicrobial stewardship. She serves on the Presidential Advisory Council on Combatting Antibiotic Resistance and has worked to help develop antimicrobial stewardship programs in several countries including India, Japan, and Italy.
Matt Weissenbach, DrPH, CPH, CIC, FAPIC
Senior Director of Clinical Affairs
Wolters Kluwer
Matt Weissenbach, DrPH, CPH, CIC, FAPIC, is the Senior Director of Clinical Affairs with Wolters Kluwer. He is responsible for leading clinical efforts in the design, development, implementation, and support of Wolters Kluwer Clinical Surveillance software solutions. He and his team focus on building strong clinical partnerships and supporting healthcare teams with guidance and resources to provide high-quality care and reach optimal patient outcomes. Dr. Weissenbach has practiced as an epidemiologist and infection preventionist for more than fifteen years. His practice and research interests include the role of clinical decision support and technology in advancing infection prevention and the implementation science of multidisciplinary approaches in antimicrobial stewardship. He earned his Doctor of Public Health and Master of Public Health degrees from the University of South Florida (USF) College of Public Health. He also serves as adjunct faculty at USF, teaching and mentoring students on emerging infectious diseases, epidemiology, and the principles of infection prevention and control. Dr. Weissenbach is board-certified in infection control and epidemiology (CIC®) and public health (CPH®). He received the designation of Fellow of the Association for Professionals in Infection Control and Epidemiology (FAPIC®) in 2020 and serves as an active member of both APIC and the Society for Healthcare Epidemiology of America.
Kalvin Yu, MD, FIDSA
Vice President of Medical Affairs, North America
BD
As the Vice President of Medical Affairs for North America, Kalvin Yu, MD, FIDSA, is responsible for providing medical and scientific leadership and operationally viable BD Solutions with clinicians and healthcare systems across the United States. Before BD, Dr. Yu was the Chief Integration Officer and Chief of Infectious Diseases at Southern California Kaiser Permanente, where he implemented multidisciplinary quality and patient safety programs among different hospitals and service lines. Dr. Yu trained at the UCLA School of Medicine and was a former Associate Professor of Infectious Disease and Global Public Health at NYU. Published research areas include patient outcomes, readmissions, and quality metric benchmarking. He was a member of the CDC Antibiotic Utilization workgroup, and has been an invited speaker at IDSA, SHEA, Pew Trusts, and Capitol Hill in Washington D.C. Dr. Yu was nominated and inducted as a Fellow in the Infectious Diseases Society of America in 2020.
Please feel free to download, print, display, or share the flyer linked below. It contains a QR code that can be used to register for this symposium.
